The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Hutchmed in Macau boost; UP Global success in Germany

Tue, 01st Mar 2022 20:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval to market fruquintinib, an inhibitor of vascular endothelial growth factor receptors, in Macau. Drugs of this type are often used to treat cancer.

----------

UP Global Sourcing Holdings PLC - Oldham, Greater Manchester-based consumer brands owner - Petra brand receives first "substantial" order from a German hypermarket retailer. "Petra, the group's recently acquired German kitchen electrical brand, is well recognised in the German market and enjoys a reputation for quality and design innovation," UP Global says. Deal is worth EUR1 million.

----------

JPMorgan Russian Securities PLC - Russia-focused investor - Says 49% of portfolio comprises of locally-listed stocks it is currently not allowed to trade in due to restrictions. Holds shares in Russian state-backed VTB Bank amounting to 1.9% of investor's portfolio. Company manager monitoring impact of sanctions and also waives management fee. Will not buyback shares during uncertain market conditions and says sanctions restrict ability to pay further dividends. "It remains the company's intention to resume quarterly dividend payments once circumstances permit," JPMorgan Russian says.

----------

Puma VCT 13 PLC - venture capital trust - Exercises over-allotment facility linked with GBP25 million fundraise. To raise further GBP5 million.

----------

Bango PLC - Cambridge-based mobile commerce company - Begins trading on OTC Markets Group's OTCQX Best Market. "Trading on OTCQX will further increase the visibility and accessibility of Bango to North American investors. OTCQX supports more transparent quotation and trading of Bango ordinary shares in US dollars during trading hours in the United States, allowing easier access for investors who prefer securities that trade domestically in US dollars," Bango adds.

----------

Omega Diagnostics Group PLC - Alva, Scotland-based medical diagnostics - Says total amount raised from fundraise is GBP5.5 million. It had planned to raise up to GBP7 million.

----------

DeepMatter Group PLC - Glasgow, Scotland-based digital chemistry data company - Signs collaboration deal with Standigm Inc, a workflow artificial intelligence drug discovery company, based in South Korea. "The first stage of the agreement is expected to generate revenues of GBP233,000. The group is now actively working towards broadening the scope of the agreement in the three-year term," DeepMatter says. "DeepMatter will provide access to its proprietary data and algorithms via its unique data and laboratory integration platform."

----------

7digital Group PLC - London-based music licensing provider - Signs deal with existing B2B music streaming service customer worth at least EUR2.2 million over three-year period. "The company has been providing services to the customer since 2016, with contract renewals on an annual basis. This latest contract expands the relationship to a long-term agreement, providing greater visibility over revenue. The company also expects the value of the contract to increase as the fast-growing customer seeks to expand its brand into further territories, which would require further licence agreements with 7digital," 7digital says.

----------

Mobile Streams PLC - London-based mobile content provider - Says monthly revenue now exceeds USD150,000. "In addition, the company has commenced the process of uploading its content, including Esports, to the Huawei App gallery and anticipates once successful these will be made available across the Huawei handset user base," Mobile Streams adds.

----------

Hardide PLC - Oxfordshire-based advanced surface coating technology developer - Delivers first production set of coated turbine blades for Ansaldo Energia Spa, a manufacturer of steam and gas turbines. "These blades are to be installed in advanced gas turbine engines with high operational flexibility that cut CO2 emissions and operational costs in a very demanding market. More orders for this application are expected to be placed during 2022," Hardide adds.

----------

Getech Group PLC - Leeds-based provider of geoscience data - Wins GBP1.2 million deals for its geoscience data and energy software products. "The contracts, which include annual and multi-year licences with new and existing customers, add to Getech's recurring revenue and orderbook," company says.

----------

Journeo PLC - Leicestershire-based transport information systems and technical services - Gets GBP2.1 million order from City of Edinburgh to upgrade real-time outdoor passenger display systems. "The purchase order includes the supply and support of over 400 optically bonded new displays as part of the second phase of a 5 year GBP4.8 million services and support contract," Journeo says.

----------

AFC Energy PLC - Cranleigh, England-based hydrogen power generation technologies provider - Says it and partner Acciona agree to deploy AFC's first hybrid fuel cell system in Spain.

----------

Phoenix Copper Ltd - British Virgin Islands-based base and precious metals production and exploration company - Under environmental, social and governance plans, Phoenix is to create the Konnex Community Advisory Team. This is to build "meaningful relationships" in communities near Empire State mine in Idaho, US.

----------

Beowulf Mining PLC - developing Kallak iron ore mine in Sweden and Aitolampi graphite mine in Finland - Invests further GBP200,000 in Vardar Minerals Ltd. Increases stake to 51% from 49%. Also notes talks with Vardar's management for final plan for drilling, including at Wolf Mountain, which has lead and zinc targets. "Drilling could start in the next 1-2 months and Beowulf would provide the funding," Beowulf adds.

----------

Mila Resources PLC - London-based gold company focused on Australia - Second drill hole at Kathleen Valley, Australia hosts sulphides akin to adjacent Bellevue gold discoveries. "Drilling continues to define a wide coherent zone of mineralisation which is open at depth and maintains a very-linear consistent zone," Mila says.

----------

88 Energy Ltd - Australia-based oil explorer in US state of Alaska - Says mobilisation of Arctic Fox rig to Merlin-2 appraisal well drilling location is now complete. "Pre-spud operations are continuing and now entering the final phase. The Merlin-2 spud date is scheduled for the week commencing 7 March 2022," 88 adds.

----------

Cloudbreak Discovery PLC - London-based natural resource project generator - Raises GBP1.5 million in share placing, to advance various project generation initiatives and for working-capital purposes. Cloudbreak places 20 million shares at 7.50p each, representing a 20% discount to Monday's closing price of 10.22p.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more
14 Sep 2023 13:09

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.